



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dennis A. Carson et al.

Title: USE OF ETODOLAC IN THE TREATMENT OF CANCER

Docket No.: 103.021US1

Serial No.: 09/589,476

Filed: June 7, 2000

Due Date: October 3, 2002

Examiner: Jerome D. Goldberg

Group Art Unit: 1614

BOX AF

Commissioner for Patents
Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ A Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (1 pg.), and copies of 6 cited documents.

Please consider this a **PETITION FOR EXTENSION OF TIME** for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By: William F. Prout
Atty: William F. Prout
Reg. No. 33,995

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: **BOX AF** Commissioner for Patents, Washington, D.C. 20231, on this 2nd day of October, 2002.


Sarah L. Reinhard
Name

Sarah L. Reinhard
Signature

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
(GENERAL)

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)



S/N 09/589476

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Dennis A. Carson et al.	Examiner:	Jerome Goldberg
Serial No.:	09/589476	Group Art Unit:	1614
Filed:	June 07, 2000	Docket:	00103.021US1
Title:	USE OF ETODOLAC IN THE TREATMENT OF CANCER		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

BOX AF

Assistant Commissioner for Patents
Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(1) and 37 C.F.R. §1.97(e)(1), Applicants state that each item of information contained in the Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

It is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if a final action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application has been mailed, the Commissioner is hereby authorized to charge the required fees to Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

Applicants note that the document, DE 2226 340 is from the same family as U.S. Patent No. 3,843,681, which was cited in the Information Disclosure Statement mailed on February 15, 2001. Enclosed are copies of all documents from the PCT not previously submitted in this matter.

RECEIVED
OCT 09 2002
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial No :09/589476

Filing Date: June 07, 2000

Title: USE OF ETODOLAC IN THE TREATMENT OF CANCER

Page 2

Dkt: 00103.021US1

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

DENNIS A. CARSON ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402

Date

October 2, 2002

By

William Prout

William Prout

Reg. No. 33,995

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 2nd day of October, 2002

Name

Sarah L. Reinhard

Signature

Sarah L. Reinhard